Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Positioning NK-kappaB in multiple myeloma.

Literature DB >> 20430962

Positioning NK-kappaB in multiple myeloma.

Bernard Klein¹.

Abstract

Entities: Disease

Year: 2010 PMID： 20430962 PMCID： PMC2997801 DOI： 10.1182/blood-2010-01-264796

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

9 in total

1. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors: Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal: Blood Date: 2003-12-04 Impact factor: 22.113

2. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Authors: Yulia N Demchenko; Oleg K Glebov; Adriana Zingone; Jonathan J Keats; P Leif Bergsagel; W Michael Kuehl
Journal: Blood Date: 2010-01-06 Impact factor: 22.113

3. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors: Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal: Blood Date: 2009-02-18 Impact factor: 22.113

4. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors: Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal: Cancer Cell Date: 2007-08 Impact factor: 31.743

5. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors: Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal: Cancer Cell Date: 2007-08 Impact factor: 31.743

Review 6. Regulation and function of NF-kappaB transcription factors in the immune system.

Authors: Sivakumar Vallabhapurapu; Michael Karin
Journal: Annu Rev Immunol Date: 2009 Impact factor: 28.527

7. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

Authors: Michel Jourdan; Jérôme Moreaux; John De Vos; Dirk Hose; Karène Mahtouk; Matthieu Abouladze; Nicolas Robert; Marion Baudard; Thierry Rème; Angela Romanelli; Hartmut Goldschmidt; Jean-François Rossi; Michel Dreano; Bernard Klein
Journal: Br J Haematol Date: 2007-06-03 Impact factor: 6.998

8. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Authors: J-F Rossi; J Moreaux; D Hose; G Requirand; M Rose; V Rouillé; I Nestorov; G Mordenti; H Goldschmidt; A Ythier; B Klein
Journal: Br J Cancer Date: 2009-10-06 Impact factor: 7.640

9. BCMA is essential for the survival of long-lived bone marrow plasma cells.

Authors: Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle
Journal: J Exp Med Date: 2004-01-05 Impact factor: 14.307

9 in total

8 in total

1. Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro.

Authors: Li Sun; Hong-xiang Wang; Xiao-jian Zhu; Pin-hui Wu; Wei-qun Chen; Ping Zou; Qiu-bai Li; Zhi-chao Chen
Journal: Acta Pharmacol Sin Date: 2013-12-30 Impact factor: 6.150

2. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.

Authors: Yun Dai; Shuang Chen; Li Wang; Xin-Yan Pei; Vanessa L Funk; Lora B Kramer; Paul Dent; Steven Grant
Journal: J Biol Chem Date: 2011-08-04 Impact factor: 5.157

3. Logic programming reveals alteration of key transcription factors in multiple myeloma.

Authors: Bertrand Miannay; Stéphane Minvielle; Olivier Roux; Pierre Drouin; Hervé Avet-Loiseau; Catherine Guérin-Charbonnel; Wilfried Gouraud; Michel Attal; Thierry Facon; Nikhil C Munshi; Philippe Moreau; Loïc Campion; Florence Magrangeas; Carito Guziolowski
Journal: Sci Rep Date: 2017-08-23 Impact factor: 4.379

4. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study.

Authors: Brenda M Birmann; Edward L Giovannucci; Bernard A Rosner; Graham A Colditz
Journal: Cancer Prev Res (Phila) Date: 2013-11-26

5. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.

Authors: Jahangir Abdi; Tuna Mutis; Johan Garssen; Frank A Redegeld
Journal: PLoS One Date: 2014-05-02 Impact factor: 3.240